Market Research Report
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) (Hematology) - Drugs In Development, 2021
|Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) (Hematology) - Drugs In Development, 2021|
Published: August 30, 2021
Global Markets Direct
Content info: 52 Pages
Delivery time: 1-2 business days
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2021, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.